Call Us With No Obligation
(877) 446-9001
24 Hours/ 7 days a week

Contact an Attorney


captcha

Yes I agree to the Terms & Conditions

Information about filing a Fentanyl patch lawsuit.

Posts Tagged ‘Subsys’

New Jersey files lawsuit against Insys over Subsys fentanyl spray fraud and false claims

Friday, November 17th, 2017

The state of New Jersey has filed a lawsuit against Insys over the fentanyl spray Subsys. The lawsuit alleges that Subsys caused the death of a New Jersey woman who was prescribed the opioid drug and put the lives of hundreds of other residents at risk. (more…)

Insys agrees to $2.9 million settlement in lawsuit over Subsys fentanyl spray marketing

Tuesday, March 21st, 2017

Insys Therapeutics – the manufacturer of the prescription fentanyl sublingual spray Subsys – has agreed to pay $2.9 million to settle a lawsuit filed in New Hampshire over the company’s marketing of the drug. The lawsuit, which was filed against Insys by the New Hampshire attorney general, accused Insys of aggressively marketing the fentanyl spray to New Hampshire residents. (more…)

Donation by fentanyl maker Insys to opponents of Arizona marijuana legalization law sparks criticism

Friday, September 23rd, 2016

Supporters of a proposed Arizona law that would decriminalize marijuana use have criticized a recent donation by Insys Therapeutics – the manufacturer of the fentanyl sublingual spray Subsys – to a group campaigning against the law. Critics say that a $500,000 donation from Insys to Arizonans for Responsible Drug Policy (ARDP) was made in an effort to boost a recently approved drug manufactured by the company based on a synthetic version of the active ingredient in marijuana. (more…)

Subsys fentanyl spray manufacturer under investigation for alleged off-label marketing

Friday, June 6th, 2014

The drugmaker Insys Therapeutics is under investigation for violation of federal laws relating to the off-label promotion of the fentanyl spray Subsys and other pharmaceutical products. Officials contend that Insys may have aggressively promoted Subsys to physicians for off-label use despite the fact that such marketing is prohibited under federal law. (more…)